News

The Peggy Lillis Foundation's CEO and Co-founder Christian Lillis discusses the organization's initiatives for C diff month, and offers a glimpse of the upcoming Scientific Symposium they are hosting next week.

The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.

Here is some important information around this pathogen and the intestinal infection.

Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.

Enteric fever (typhoid or paratyphoid fever) infection in travelers returning to the US is likely resistant to ciprofloxacin, and with some cases also resistant to ceftriaxone, CDC investigators advise treatment guided by susceptibility.

The 2026 Antimicrobial Resistance Threats Report from the CDC categorizes 19 bacterial and fungal pathogens by level of threat to health in the US.

Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.

A CDC analysis of Antimicrobial Resistance Laboratory Network data found pediatric carbapenemase-producing CRE incidence in the United States rose 92% from 2019 to 2024, driven mostly by NDM-producing organisms.

Here is a case that was linked to a unique travel history and led to a series of acute health issues.

Deborah Fuller, PhD, provides commentary around the data, and advantages of the technology.

CDC reports 10,772 confirmed Ebola cases and 5234 deaths, making this the second-largest outbreak on record. Kenya and Nigeria have reported cases.

IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.

IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.

New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.

Recent urinary tract infection guideline updates from multiple international medical societies highlight evolving recommendations, including a major shift in classification, moving from anatomy- and risk factor–based definitions toward distinguishing localized from systemic infections.

Confirmed US measles cases rose 6.8% this week to 5,182, more than double the 2025 total, as three states reported measles-associated deaths.

Li Tao, PhD, discusses early US uptake of twice-yearly lenacapavir, faster prescription-to-injection timelines, and how ACA coverage milestones tracked with zero cost sharing and HIV diagnoses.

In a target trial emulation using N3C data, adults prescribed metformin within six days of SARS-CoV-2 infection had about half the risk of long COVID or death within six months.

Approximately half of Long COVID patients were found to have meaningful symptom improvement within 3 years after acute infection and more than a quarter had completely remitted, in a large prospective cohort study.

Charles M. Walworth, MD, of Labcorp discusses a new hepatitis D reflex pathway, internal data showing 8.3% of HBsAg-positive patients screened for HDV, and lessons from hepatitis C reflex testing.

The antifungal pipeline currently contains 22 agents in the clinical program and many more in the pre-clinical program. Novel products in the clinical program are especially encouraging.

Dr. Reddy’s generic twice-yearly lenacapavir received FDA tentative approval for HIV PrEP. It is expected to cost $40 a year in 120 low- and middle-income countries (LMICs), with first supplies due by the end of 2026.

David Altarac, MD, discusses 2025 SENTRY data, ESBL considerations in empiric therapy, and where ceftobiprole fits alongside ceftaroline in S aureus bacteremia.

A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.

Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.

Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.

Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.

In a national survey of 959 US adults, 27.9% said they had exaggerated or made up symptoms to obtain antibiotics, most often cold-like symptoms, with implications for outpatient stewardship.